Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues

Oguri,Tetsuya; Ozasa,Hiroaki; Uemura,Takehiro; Takakuwa,Osamu; Kunii,Eiji; Kasai,Daishi; Ohkubo,Hirotsugu; Miyazaki,Mikinori; Maeno,Ken; Sato,Shigeki

doi:10.3892/ol.2012.773

Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues

Authors:
- Tetsuya Oguri
- Hiroaki Ozasa
- Takehiro Uemura
- Osamu Takakuwa
- Eiji Kunii
- Daishi Kasai
- Hirotsugu Ohkubo
- Mikinori Miyazaki
- Ken Maeno
- Shigeki Sato
View Affiliations

Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Published online on: June 26, 2012 https://doi.org/10.3892/ol.2012.773
Pages: 571-575

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytotoxic nucleoside analogues are widely used in cancer chemotherapy. We used the cytosine arabinoside (Ara-C)-resistant erythroleukaemia cell line K562 and the Ara-C-sensitive myeloid leukaemia cell line HL60 to examine the differential expression of molecular markers. We found increased expression levels of deoxycytidine kinase (dCK) and human equilibrative nucleoside transporter 1 (hENT1) and decreased levels of multidrug resistance protein 5 (ABCC5) and ribonucleoside reductase subunit M1 (RRM1) expression in Ara-C-sensitive HL60 cells. We previously established the pemetrexed (MTA)-resistant small cell lung cancer cell lines PC6/MTA-0.4 and PC6/MTA-1.6 and found that MTA-resistant cells are more sensitive to gemcitabine (GEM) and Ara-C compared with parental PC-6 cells. We examined the molecular markers for GEM and Ara-C sensitivity in MTA-resistant cells and found increased gene expression of dCK and hENT1. Furthermore, treatment with MTA resulted in increased expression of dCK and hENT1 and decreased expression of ABCC5 and RRM1, concomitant with the alteration of the resistance to Ara-C in Ara-C-resistant K562 cells. These results provide evidence that the chemotherapeutic activity of the combination of MTA and cytotoxic nucleoside analogues is synergistic with regard to the alteration of metabolic molecules.

View Figures

View References

1	Galmarini CM, Mackey JR and Dumontet C: Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 3:415–424. 2002. View Article : Google Scholar : PubMed/NCBI
2	Heinemann V, Schulz L, Issels RD and Plunkett W: Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 22(4 Suppl 11): 11–18. 1995.PubMed/NCBI
3	Achiwa H, Oguri T, Sato S, Maeda H, Niimi T and Ueda R: Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 95:753–757. 2004. View Article : Google Scholar : PubMed/NCBI
4	Oguri T, Achiwa H, Sato S, et al: The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small-cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther. 5:1800–1806. 2006. View Article : Google Scholar : PubMed/NCBI
5	Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 5:19–33. 2002.
6	Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM and Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
7	Oguri T, Achiwa H, Muramatsu H, et al: The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 256:112–119. 2007. View Article : Google Scholar
8	Hazarika M, White RM, Johnson JR and Pazdur R: FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 9:482–488. 2004. View Article : Google Scholar : PubMed/NCBI
9	Cohen MH, Justice R and Pazdur R: Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist. 14:930–935. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ozasa H, Oguri T, Uemura T, et al: Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci. 101:161–166. 2010. View Article : Google Scholar : PubMed/NCBI
11	Uemura T, Oguri T, Ozasa H, et al: ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 101:2404–2410. 2010. View Article : Google Scholar : PubMed/NCBI
12	Oguri T, Bessho Y, Achiwa H, et al: MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther. 6:122–127. 2007. View Article : Google Scholar : PubMed/NCBI
13	Månsson E, Flordal E, Liliemark J, et al: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 65:237–247. 2003.
14	Månsson E, Spasokoukotskaja T, Sällström J, Eriksson S and Albertioni F: Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res. 59:5956–5963. 1999.PubMed/NCBI
15	Ma CX, Nair S, Thomas S, Mandrekar SJ, et al; North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly & Company. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 23:5929–5937. 2005. View Article : Google Scholar : PubMed/NCBI
16	Tallman MS, Gilliland DG and Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 106:1154–1163. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kern W and Estey EH: High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer. 107:116–124. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ohe Y, Ichinose Y, Nakagawa K, et al: Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 14:4206–4212. 2008. View Article : Google Scholar : PubMed/NCBI